Click on image to view larger version.
FIGURE 4. (A) CT scans before (left), 3 mo after (middle), and 12 mo after (right) last therapy with 177Lu-octreotate in patient 3 with liver metastases of an operated neuroendocrine pancreatic tumor. Disappearance of tumor sites (arrows, left) at 3-mo follow-up (middle). Recurrence of tumors at 12-mo follow-up (right). (B) Planar scans of abdomen, 3 d after injection of 7.4 GBq 177Lu-octreotate (left and middle) and 1 d after the injection of 222 MBq 111In-octreotide. Image at 3 d shows clear accumulation in tumor sites in liver after first therapy (left) and loss of intensity of uptake in liver lesions after last therapy (middle). Octreotide scan at 3-mo follow-up was negative (right). (C) Course of chromogranin A (CgA; normal upper limit, 100 ng/mL) and neuron-specific enolase (NSE; normal upper limit, 16.3 µg/L) during and after 177Lu-octreotate therapy and chemotherapy.
